NCT01460160
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
PHASE2
COMPLETED
NCT01460160
INTERVENTIONAL
A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
* Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)
* Age \>1 year and \< less than 18 years old
* Induction chemotherapy ≤ 14 days according to institutional standard of care
* Adequate liver, renal and cardiac function
Exclusion Criteria:
* Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor
* Extramedullary involvement of the testicles
* Active systemic bacterial, fungal or viral infection
* Down syndrome
Leukemia, Pediatric
- TREATMENT
-
- Type: DRUG
- Name: Dasatinib
- Description: Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
- Arm Group Labels: Arm 1: Dasatinib
- Bristol-Myers Squibb